Novelmed Therapeutics

This study tests a new drug called NM8074 in 12 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking Soliris. The goal is to see if NM8074 is safe and can better control the disease by reducing red blood cell destruction and the need for blood transfusions…

This early-stage study tests a new drug, NM8074, in 18 adults with C3 glomerulopathy, a rare kidney disease where the immune system attacks the kidneys. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants will receive …

This study tests a new drug called NM8074 in 12 adults with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots, low platelets, and kidney damage. The goal is to see if the drug can stop the disease process and improve blood counts and kidney funct…

This study is testing whether an experimental drug called NM8074 can reduce protein loss in urine for people with IgA nephropathy, a kidney disease. Researchers will give the drug to 10 adult patients for 99 days and measure changes in their urine protein levels and kidney functi…